Fresenius Medical Care
Fresenius Medical Care is the world's largest dialysis company, operating about 3,600 dialysis clinics worldwide and treating roughly 292,000 patients as of end-2025, with the United States as its largest market. The company provides in-center hemodialysis, home dialysis products (including the NxStage system), and dialysis equipment manufacturing, forming one half of a duopoly with DaVita that controls roughly three-quarters of U.S. dialysis facilities. Formerly controlled by Fresenius SE, it became an independent AG in 2023; Fresenius SE remains its largest shareholder with about a quarter of the shares.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-26. Score revised 2026-09-26: 65 → 66.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Fresenius merged its dialysis products business with W.R. Grace's National Medical Care, creating the world's largest dialysis provider with NMC's roughly 500 clinics, and listed in Frankfurt and New York. It inherited a federal investigation into NMC's billing of unnecessary tests and lab kickbacks. From 1998 large chains began buying independent clinics at scale, while Medicare's separate payment for ESA drugs rewarded heavy dosing.
Three NMC subsidiaries pleaded guilty and the company paid a record $486 million, accepting a sweeping corporate integrity agreement. Fresenius kept buying independent clinics, part of more than 1,200 chain acquisitions from 1998 to 2010 that research later linked to less-skilled staffing and worse outcomes, and raised its dividend every year. ESAs became Medicare's largest drug expense, with average dialysis doses by 2006 about three times 1991 levels.
The $3.5 billion Renal Care Group purchase, cleared after 91 clinic divestitures, took Fresenius to about 1,500 North American clinics. The FDA's 2007 boxed warning on ESAs and Medicare's 2011 bundled payment ended separately billed drugs as a profit engine and pushed the industry toward cost cutting and consolidation. Unknown at the time, Fresenius began bribing foreign health officials in 2007, and in November 2011 it warned only its own clinics about a GranuFlo cardiac-arrest risk.
Closing the Liberty Dialysis deal (60 clinics divested) cemented the Fresenius-DaVita duopoly. Weeks later the FDA initiated a Class I recall of GranuFlo/NaturaLyte, leading to a $250 million settlement in 2016, and in 2015 Fresenius ran nearly half of Medicare's one-star facilities. The company went to court in 2017 to preserve American Kidney Fund premium assistance, opposed California's staffing-ratio bill, and put about $33 million into defeating Proposition 8 in 2018.
Fresenius closed its $2 billion NxStage purchase, approved 3-2 over two dissenting FTC commissioners, then paid $231 million to resolve foreign bribery charges and $5.2 million over hepatitis B overbilling. It sued to block California's AB 290 anti-steering law, a Fresenius clinic's $540,842 bill drew national coverage, and it spent about $57 million more defeating Propositions 23 and 29. The FME25 program announced up to 5,000 job cuts in 2021, and in 2022 the DOJ joined a false-claims suit over allegedly unnecessary vascular procedures.
Helen Giza, who had led the FME25 restructuring, became CEO and accelerated it: Fresenius converted to a stand-alone AG in November 2023, divested 230 facilities in 2024 and moved Concord machine production to Mexico. California caregivers unionized with SEIU-UHW and struck in 2023 and 2024 over understaffing and alleged union busting. Scrutiny widened, with three state attorneys general joining the vascular false-claims case, an FDA warning letter over toxic-compound leaching from machine tubing, an FTC probe of medical-director noncompetes and a 2025 price-fixing class action.
At its June 2025 Capital Markets Day Fresenius launched FME Reignite, pairing mid-teens margin ambitions with a 30-40% dividend payout and regular share buybacks. The first EUR 1 billion buyback was completed in April 2026 and a second began in May, while the company exited about 100 U.S. clinics, including sole rural centers in Alabama and Kentucky, and outsourced delivery jobs to Ryder. Legal pressure continued (a Washington antitrust probe, an August 2026 FDA warning letter), though Fresenius won the AB 290 appeal and began a large-scale rollout of hemodiafiltration machines.
Alternatives
Fresenius and DaVita ran 77.1% of U.S. dialysis facilities in 2019, up from 59.1% in 2005, and that year 32.5% of Americans lived in areas where no other dialysis provider operated. In-center hemodialysis patients need treatment about three times a week and can only use clinics within reach that accept their insurance, so where there is a choice it is usually the other half of the duopoly. Independent facilities fell to 10.6% of the total by 2019, and nonprofit providers such as Dialysis Clinic, Inc. serve only part of the country. Home dialysis is a partial exit, but Fresenius also owns NxStage, the leading home-hemodialysis machine maker.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (65 events)
NMC fraud investigation inherited by newly formed FMC
When Fresenius Medical Care was created through the merger with W.R. Grace's National Medical Care, it inherited a federal fraud case that had begun while NMC was still owned by Grace. According to a later federal court ruling, the HHS Office of Inspector General opened criminal and civil investigations in 1995, following whistleblower suits filed from 1993 onward. NMC units were under scrutiny for billing Medicare for unnecessary blood tests and paying kickbacks to steer lab business to its LifeChem laboratory. The case would ultimately end in the $486 million settlement announced in January 2000.
Fresenius Medical Care formed from NMC merger
Fresenius SE merged its dialysis business with W.R. Grace's National Medical Care to create Fresenius Medical Care, instantly becoming the world's largest dialysis provider. NMC operated approximately 500 clinics serving 40,000 patients, giving the combined entity dominant scale in both equipment manufacturing and clinical services.
Fresenius Medical Care lists on Frankfurt and NYSE
Fresenius Medical Care began trading on both the Frankfurt Stock Exchange and the New York Stock Exchange, raising capital for further expansion. The dual listing gave the company access to deep capital markets, funding the acquisition-driven growth strategy that would consolidate the U.S. dialysis market over the following decades.
Balanced Budget Act extends Medicare secondary payer period
The Balanced Budget Act of 1997 extended the Medicare Secondary Payer period for ESRD patients from 18 to 30 months, meaning commercially insured patients would stay on private insurance longer before Medicare became primary. This policy strengthened the financial incentive to keep patients on commercial insurance, which paid 3-4x Medicare rates, and deepened patient lock-in to their initial provider during the extended coordination period.
Large dialysis chains begin systemic acquisition of independents
Beginning in the late 1990s, Fresenius and DaVita (then Total Renal Care) acquired independent dialysis clinics at scale. Between 1998 and 2010, large chains made more than 1,200 first-time acquisitions of independent facilities. Most of these deals were too small to require Hart-Scott-Rodino pre-merger notification, allowing the chains to consolidate local markets one clinic at a time without federal merger review. Meanwhile, as the LPE Project notes, Medicare's per-session dialysis rate stayed nearly flat from 1980 to 2011, pricing out hospital-based and non-profit facilities as treatment shifted to for-profit chains.
Fresenius pays record $486 million Medicare fraud settlement
Three National Medical Care subsidiaries pleaded guilty to billing Medicare for unnecessary medical tests and paying kickbacks for lab business, resulting in $101 million in criminal fines and $385 million in civil False Claims Act settlement. Inducements included yacht rentals and hunting trips to Alaska to steer lab testing business. The company agreed to the most comprehensive corporate integrity agreement ever imposed.
Fresenius's clinic expansion funded through steady dividend growth
By 2004, Fresenius Medical Care had established a pattern of annual dividend increases, with the split-adjusted dividend rising every year from EUR 0.17 for 1997 to EUR 0.34 for 2003. The company used its vertically integrated model (manufacturing equipment and operating treatment clinics) to fund both acquisitions and rising shareholder distributions during the consolidation wave.
ESA drug billing becomes dialysis industry profit engine
Under Medicare's fee-for-service payment for erythropoiesis-stimulating agents (adopted in 1991), combined with a composite dialysis rate that was losing real value, dialysis providers including Fresenius had a financial incentive to increase their use of drugs like Epogen. A 2017 American Journal of Nephrology review found that the mean ESA dose for US dialysis patients rose about four-fold between 1991 and 2005. By the beginning of 2005, ESAs had become the single largest drug expenditure in the entire Medicare program, with annual spending on dialysis patients approaching $2 billion. Dosing decisions were invisible to patients even as trial evidence emerged that excessive use could cause harm.
Fresenius announces $3.5 billion Renal Care Group acquisition
Fresenius Medical Care agreed to acquire Renal Care Group, the third-largest U.S. dialysis provider, for approximately $3.5 billion ($48 per share). RCG operated approximately 450 clinics serving 32,000 patients across 32 states. The FTC required divestiture of 91 clinics to approve the deal, but the acquisition still massively expanded Fresenius's U.S. footprint to approximately 1,500 clinics.
FDA mandates ESA black box warning over safety risks
On March 9, 2007 the FDA added a boxed warning to erythropoiesis-stimulating agents (ESAs) like Epogen after trials linked targeting higher hemoglobin levels to cardiovascular events and death, recommending the lowest dose needed to avoid transfusion. Average ESA doses for dialysis patients in 2006 were three times higher than in 1991, driven partly by Medicare's separate per-unit payment for the drugs. The warning began to curb one of the dialysis chains' most lucrative profit centers, which Medicare's 2011 bundled payment then eliminated.
Medicare bundled payment reform takes effect for dialysis
CMS implemented the ESRD Prospective Payment System, bundling payment for dialysis treatments, injectable drugs (including ESAs), and lab tests into a single per-treatment rate of approximately $230. The reform eliminated the separate, highly profitable reimbursement for ESAs and shifted the industry's financial incentive structure toward cost reduction and consolidation, accelerating acquisitions of smaller independent clinics.
Court awards $82.6 million against Fresenius for home dialysis billing fraud
U.S. District Court found Renal Care Group and Fresenius Medical Care recklessly disregarded federal law when billing Medicare for home dialysis supplies from 1999 to 2005, awarding $82.6 million in a whistleblower case. The defendants were prohibited from and not qualified to bill Medicare for these home dialysis patients. A federal appeals court later reversed the judgment.
Fresenius agrees to acquire Liberty Dialysis and American Access Care for $2.1 billion
Fresenius Medical Care agreed in August 2011 to acquire Liberty Dialysis Holdings (the third-largest U.S. dialysis provider, with 260 clinics and about 19,000 patients) for about $1.7 billion and American Access Care (28 vascular access centers) for $385 million. The FTC required divestiture of 60 clinics in 43 local markets, 17 of which would otherwise have become monopolies, before the Liberty deal closed in February 2012.
GranuFlo Class I recall follows cardiac-risk memo kept in-house
In November 2011 Fresenius distributed an internal memo to its own dialysis centers linking improper use of its GranuFlo/NaturaLyte dialysate to a higher risk of sudden cardiac arrest, but it did not alert other dialysis centers using the products. It did not alert them until March 2012, when the FDA initiated a Class I recall, and product liability suits followed.
Fresenius operates half of Medicare's lowest-rated dialysis facilities
Modern Healthcare reported that under Medicare's new star-rating system, Fresenius facilities accounted for nearly half of all one-star dialysis facilities nationwide (259 of 545 in the lowest tier), while only 53 Fresenius facilities earned five stars. DaVita by comparison had 40 one-star facilities and 324 five-star facilities. CMS built the ratings from nine publicly reported quality measures, including standardized transfusion, mortality and hospitalization ratios and Kt/V dialysis adequacy. Fresenius attributed part of the gap to inconsistent data collection on some measures.
Fresenius shareholders approve 18th consecutive dividend increase
At its May 2015 annual general meeting, Fresenius Medical Care's shareholders approved the company's 18th consecutive dividend increase, raising the dividend to EUR 0.78 from EUR 0.77 per share. The vertically integrated model of manufacturing dialysis equipment and operating treatment clinics generated margins that funded both acquisitions and rising distributions.
Fresenius agrees to $250 million GranuFlo/NaturaLyte settlement
Fresenius Medical Care North America reached an agreement in principle to pay $250 million to resolve U.S. product liability litigation over its GranuFlo and NaturaLyte acid concentrates, provided 97% of plaintiffs joined, with insurers funding $220 million. The company said the product remained on the market unchanged and was safe and effective when used as directed.
Fresenius and DaVita win court order blocking CMS premium assistance rule
Fresenius Medical Care joined DaVita, U.S. Renal Care and the patient group Dialysis Patient Citizens, with the American Kidney Fund's support, in suing in federal court in Texas over a December 2016 CMS interim final rule that would have restricted third-party premium assistance for dialysis patients. The court granted a temporary restraining order in January 2017 and later a preliminary injunction. The industry funds the AKF program, which pays patients' commercial premiums, and commercial plans pay far more than Medicare.
California SB 349 staffing ratio bill withdrawn under industry pressure
California Senate Bill 349, the Dialysis Patient Safety Act, would have mandated one nurse per 8 patients and one technician per 3 patients, compared with state averages of about 1:12 and 1:4. The dialysis industry, including a coalition in which Fresenius and DaVita took part, opposed it and projected it could close up to 20% of clinics. The bill was withdrawn in fall 2017 amid insufficient legislative support and signs the governor would not sign it.
Insurers accuse dialysis industry of steering patients through AKF premium aid
A coalition of insurers, employers and unions, including America's Health Insurance Plans, the Blue Cross Blue Shield Association and SEIU, asked HHS to close a loophole letting dialysis providers use the American Kidney Fund's premium assistance, which Fresenius and DaVita largely fund, to steer patients from Medicare and Medicaid to better-paying commercial plans. Their letter cited a 2017 J.P. Morgan report estimating that providers' return on 'charitable' AKF donations likely exceeded 500%. The AKF denied that donors influence grant decisions.
Research reveals acquired clinics reduce staffing and transplant referrals
A study by Duke economists presented at the FTC's microeconomics conference (later published in the Quarterly Journal of Economics) examined more than 1,200 independent dialysis facilities acquired by large chains between 1998 and 2010. Acquired facilities replaced skilled nurses with less-skilled technicians, increased patient loads per employee by 11.9%, and gave patients 128.9% higher doses of Epogen. New patients were 9.4% less likely to be waitlisted for or receive a kidney transplant, survival fell by 1.3-3.0%, all-cause hospitalizations rose 4.5%, and hospitalizations for septicemia rose 10%.
Dialysis industry spends record $111 million to defeat California Prop 8
The dialysis industry, led by DaVita (about $66 million) and Fresenius (about $33 million), raised about $111 million to defeat California Proposition 8, which would have capped clinic revenue at 115% of patient-care costs. The proposition, backed by SEIU-UHW, was defeated about 60-40. The AP reported it was the most any one side had spent on a U.S. ballot measure since at least 2002.
FTC requires bloodline tubing divestiture for NxStage merger
The FTC approved Fresenius Medical Care's $2 billion acquisition of NxStage Medical, the leading home hemodialysis device maker, on a 3-2 vote, requiring divestiture of NxStage's bloodline tubing set business to B. Braun Medical. Commissioners Rohit Chopra and Rebecca Kelly Slaughter dissented, warning the merger could foreclose rivals and inhibit new entry into home hemodialysis.
Fresenius pays $231 million for FCPA bribery in 17 countries
Fresenius Medical Care agreed to pay $231 million ($84.7 million criminal penalty, $147 million SEC disgorgement) to resolve charges that it bribed government health officials in at least 17 countries between 2007 and 2016. Methods included sham consulting contracts in Angola, check-cashing schemes in Saudi Arabia, and funneling nearly $30 million in bribes through third-party intermediaries across Africa, the Middle East, and Asia.
NBC report exposes $540,842 dialysis bill at Fresenius clinic
NBC News reported a patient billed $540,842 for 14 weeks of dialysis at a Fresenius clinic, with charges of $13,867 per session -- approximately 59 times the $235 Medicare rate. The insurer paid only $16,242, and the clinic billed the patient for the $524,600 balance. The case illustrated the extreme pricing opacity in commercial dialysis billing, where patients discover costs only after treatment.
Fresenius pays $5.2 million for Medicare hepatitis B overbilling
Fresenius Medical Care agreed to pay $5.2 million to resolve allegations that it tested dialysis patients for hepatitis B surface antigen more frequently than medically necessary and billed Medicare for the unnecessary tests from February 2003 to end of 2010. In many cases, tests were ordered against physicians' orders and without documenting medical necessity.
California enacts AB 290 anti-steering law for dialysis patients
Governor Gavin Newsom signed AB 290, which restricted dialysis providers and third parties like the American Kidney Fund from steering, directing, or advising patients regarding health insurance options. Fresenius, DaVita, and U.S. Renal Care sued in federal court in November 2019, and the court granted a preliminary injunction blocking the law in December 2019, before it took effect. In January 2024 the companies won a partial ruling that the law did not narrowly advance the state's interest.
Dialysis industry spends $105 million to defeat California Prop 23
DaVita and Fresenius contributed a combined $96.6 million ($66.8 million from DaVita, $29.8 million from Fresenius) to defeat California Proposition 23, which would have required a physician present during dialysis treatments. Voters rejected the measure 63-37, marking the second consecutive defeat for SEIU-backed dialysis regulation in California.
Fresenius announces up to 5,000 job cuts in FME25 cost-cutting program
Alongside its third-quarter 2021 results, Fresenius Medical Care unveiled the FME25 transformation program to cut its annual cost base by EUR 500 million by 2025, anticipating a reduction of up to 5,000 full-time positions worldwide. The target was later raised to EUR 750 million, and accumulated savings reached EUR 804 million by the end of 2025.
Study finds acquisitions of independent dialysis clinics spiked after 2011 payment reform
A JAMA Health Forum cohort study found that the share of U.S. dialysis facilities owned by small chains or independents fell from 29% in 2006 to 15% in 2016, mostly through acquisitions rather than closures. The odds of acquisition were 3.48 times higher after Medicare's 2011 bundled Prospective Payment System took effect, with a spike immediately after the reform. The authors noted that large for-profit chains such as Fresenius and DaVita had grown into a duopoly and that chain acquisition has been linked to worse patient outcomes.
DOJ joins False Claims Act lawsuit over unnecessary vascular procedures
The U.S. Department of Justice intervened in a whistleblower lawsuit against Fresenius Vascular Care, alleging the company performed unnecessary fistulagrams and angioplasties on dialysis patients from January 2012 to June 2018 and billed Medicare and other programs for them. The complaint alleges that for a sample of 60 patients at New York facilities, at least 1,288 of 2,303 angioplasties (55.9%) were medically unnecessary, and cites internal documents and a Fresenius-led study showing little clinical benefit. Fresenius disputes the allegations.
Third California dialysis ballot measure defeated with $86 million campaign
California Proposition 29, nearly identical to Prop 23, was rejected by about 68% of voters. The No on 29 committee raised over $86.4 million, including $52.7 million from DaVita and $27.3 million from Fresenius. Across three election cycles (2018-2022), opposition campaigns raised roughly $300 million to defeat ballot measures that would have imposed profit caps and clinic staffing requirements, with Fresenius contributing roughly $90 million.
Helen Giza appointed CEO amid leadership turmoil
Helen Giza was named CEO after predecessor Dr. Carla Kriwet departed due to strategic differences after just two months in the role. Giza, previously CFO and Chief Transformation Officer heading the FME25 restructuring program, accelerated cost-cutting initiatives. Her appointment solidified the company's shift toward aggressive margin optimization through workforce reduction and facility divestitures.
D.C. Attorney General subpoenas Fresenius over American Kidney Fund market allocation
Fresenius Medical Care Holdings received a subpoena from the Attorney General for the District of Columbia concerning the activities of the American Kidney Fund, grounded in antitrust concerns including market allocation within the District. Fresenius disclosed that it was cooperating with the investigation.
Workers protest understaffing at Fresenius dialysis clinics
SEIU-UHW organized protests at several Fresenius Kidney Care and Satellite Healthcare clinics in California over chronic understaffing at 20 recently unionized facilities. A Fresenius technician said the caregiver-to-patient ratio had risen from 1:3 to 1:8 over the years, and to 1:12 when staff called in sick. He described working from 3 a.m. to 7 p.m. and returning just after midnight for another 13-hour shift. In a 2024 short-staffing report, SEIU-UHW quoted a Fresenius registered nurse saying caregivers were working 48 to 60 hours a week with little sleep between shifts.
First-ever dialysis worker strike in U.S. history
More than 500 dialysis caregivers at Fresenius Kidney Care and Satellite Healthcare clinics launched a two-day strike on September 25-26, 2023 at about two dozen California clinics, which SEIU-UHW called the first strike at dialysis clinics in U.S. history. Workers cited unfair labor practices, understaffing, and management's refusal to bargain. Ninety-nine percent of workers had voted to authorize the strike.
NY Attorney General sues Fresenius over unnecessary vascular surgeries
New York Attorney General Letitia James, with the attorneys general of Georgia and New Jersey, sued Fresenius Vascular Care, alleging it subjected kidney dialysis patients, including elderly people, people of color and low-income individuals, to unnecessary invasive procedures to increase revenue and defrauded Medicaid. The complaint alleges medical directors were trained on the philosophy to 'simply increase revenue and decrease expense.'
Fresenius Medical Care converts to stand-alone AG, deconsolidated from Fresenius SE
The change of Fresenius Medical Care's legal form from a KGaA to a stock corporation (AG) took effect on registration, ending its consolidation into Fresenius SE. Fresenius SE kept 32% of the share capital and remained the largest shareholder.
FDA warning letter faults Fresenius over toxic-compound leaching from dialysis machine tubing
The FDA issued a warning letter after inspecting Fresenius's North American device operations, finding that Fresenius was told on December 3, 2020 of PCB emissions from silicone tubing in its 2008 series hemodialysis machines but did not open a corrective action until June 15, 2022 or recall devices until November 25, 2022, and that it failed to adequately investigate the potential health impact on patients.
SEIU-UHW demands Congressional accountability for dialysis companies
SEIU-UHW held a Capitol Hill press conference with Representatives Lofgren, Schiff, and Porter on the understaffing crisis at Fresenius, DaVita and Satellite clinics. The union noted Fresenius had received more than $2 billion from Veterans Administration dialysis contracts since 2014 and asked lawmakers to investigate the companies' labor practices and staffing.
NLRB prosecutors issue complaints over Fresenius response to dialysis union drive
An SEIU-UHW report said Fresenius and Satellite Healthcare faced charges of retaliatory firings, retaliatory discipline, threats and bad-faith bargaining after California dialysis workers organized, and that NLRB prosecutors had already issued complaints against both companies. A Fresenius technician said unionized clinics were denied staffing support and annual raises, and that strikebreakers were paid over $70 an hour while some workers earned $17.
Fresenius closes Concord plant, moves manufacturing to Mexico
Fresenius Medical Care filed a WARN notice covering 309 workers as it planned to close its Concord, California manufacturing plant, moving all dialysis machine production to its facility in Reynosa, Mexico, with layoffs running from August 2024 to mid-2025. CEO Helen Giza told investors the move was meant to reduce costs and improve margins.
FTC opens antitrust investigation into dialysis duopoly noncompetes
The Federal Trade Commission launched an investigation into DaVita and Fresenius Medical Care over their use of noncompete agreements with medical directors. The contracts ban physicians from serving as medical directors at any competing facility, including patients' homes, in the same geographic market. The investigation targets practices dating back to at least 2016 and could reshape the competitive landscape for independent and home dialysis providers.
Hundreds of dialysis caregivers picket across California
Hundreds of dialysis caregivers at 26 Fresenius Kidney Care, Satellite Healthcare, and U.S. Renal clinics held informational pickets across California in July and August 2024 over understaffing, unsafe conditions and low wages. A letter from more than 400 workers warned that patients can lose consciousness, have a seizure or bleed out within minutes without adequate staffing.
Six-day dialysis worker strike across 37 California clinics
Nearly 900 dialysis workers held a six-day unfair labor practice strike from October 14-19, 2024 at 37 DaVita, Fresenius, Satellite, and U.S. Renal clinics in California. Workers alleged illegal union-busting tactics, including threats and retaliation against union supporters. SEIU-UHW said management at one Fresenius clinic in the San Diego region spent more than $650,000 in 2023 to oppose unionization.
Fresenius divests 230 facilities with 8,200 employees in 2024
Fresenius Medical Care continued portfolio optimization in 2024, exiting clinic operations in all Latin American countries, Sub-Saharan Africa, and Turkey, and divesting Cura Day Hospitals in Australia. Assets divested in 2024 comprised 230 facilities, 8,200 employees, and about 33,800 dialysis patients. Operating income excluding special items grew 18% and revenue was about EUR 19.3 billion. FME25 savings reached EUR 567 million by end-2024, and the target was raised to EUR 750 million.
DOJ opens inquiry into ultrasound billing at Fresenius's Azura Vascular Care
Fresenius Medical Care Holdings received a civil investigative demand from the U.S. Department of Justice concerning whether its subsidiary Azura Vascular Care billed for intravascular ultrasound procedures that were not medically necessary and were upcoded. The company said it was cooperating; the matter was still open in its 2025 annual report.
Class action alleges DaVita-Fresenius antitrust conspiracy
A proposed class-action lawsuit filed on behalf of the United Food and Commercial Workers Local 1776 benefits fund alleged that DaVita and Fresenius conspired to allocate U.S. markets, inflate treatment prices by billions, and collude through the American Kidney Fund to steer patients to lucrative commercial insurance. The complaint alleged prices would have been significantly lower absent the conspiracy.
Fresenius launches EUR 1 billion share buyback program
Fresenius Medical Care initiated a EUR 1 billion share buyback program with an accelerated first tranche of EUR 600 million completed by December 2025 (14.1 million shares repurchased for EUR 586 million). A second tranche of approximately EUR 414 million began in January 2026. The buyback coincided with 27% operating income growth in 2025 and a 3% dividend increase to EUR 1.49 per share.
Study confirms dialysis duopoly inflates commercial insurance prices
A JAMA Health Forum analysis by Duke economists, reported by Healio, found that DaVita and Fresenius's share of U.S. dialysis centers grew from 59.1% in 2005 to 77.1% in 2019. In 2019, commercial insurers paid about $495 more per hemodialysis session in service areas with a large chain than in areas without one. Medical director pay averaged about $565 per patient in single-chain markets, and 32.5% of U.S. residents lived in areas where only DaVita or Fresenius facilities were available.
Caregivers at 31 California dialysis clinics picket over stalled first contract
More than 700 SEIU-UHW caregivers at Fresenius Kidney Care, Satellite Healthcare and U.S. Renal clinics held a one-day informational picket at 31 California clinics, saying the companies were bargaining in bad faith and dragging out negotiations on a first contract while short staffing cut patients' treatments short.
Dialysis workers file safety complaints at Fresenius California clinics
Dialysis healthcare workers filed complaints with local public health departments across California, alleging chronic understaffing, infection control failures such as visible blood stains and improper disinfection, unsanitary facilities, and unsafe equipment at Fresenius and Satellite Healthcare clinics. They asked for investigations into conditions that they said led to skipped safety checks and missed treatments.
Washington AG joins FTC and Florida in probing Fresenius physician noncompetes
Fresenius received a civil investigative demand from the Washington Attorney General investigating possible anticompetitive conduct in acquiring medical director services and providing dialysis. It followed a similar Florida Antitrust Act demand in May 2025 and the FTC's April 2024 demands on restrictive covenants such as physician noncompetes, all still open in early 2026.
Senator Blumenthal presses FTC to act on DaVita-Fresenius duopoly
Senator Richard Blumenthal wrote to FTC Chairman Andrew Ferguson that most dialysis patients depend on DaVita and Fresenius, which control at least 77% of the national market, citing reports of understaffed clinics, anti-union tactics and physician noncompetes. He asked for a briefing on the FTC's investigation and for robust enforcement.
Fresenius outsources delivery to Ryder, issues layoff notices in several states
Fresenius filed WARN notices for 56 employees at its Chester, New York distribution plant, part of cuts that also hit sites in Oregon, Ohio, Texas and Wisconsin, after deciding to transfer its North American final-mile delivery network to Ryder from April 28, 2026. The company called it part of its ongoing transformation.
Fresenius closes only dialysis centers in two rural Alabama counties
Fresenius confirmed it would close its only dialysis center in Wilcox County, Alabama on March 20, less than a week after announcing the closure of its Tuskegee center, the only one in Macon County. Wilcox patients faced round trips of 60 to 110 miles to the nearest alternatives in a state with one of the highest kidney failure rates.
Operating income up 27% in 2025; FME25+ savings target raised to EUR 1.2 billion
Fresenius reported 27% operating income growth for 2025 and an 11.3% margin, crediting FME25+ efficiencies, TDAPA add-on payments and favorable rate and payor mix effects. The cost program reached EUR 804 million in accumulated savings and was extended to EUR 1.2 billion by end-2027; divestitures since 2023 totaled 391 facilities, about 12,600 employees and 53,600 patients.
Only dialysis clinic in Kentucky's Muhlenberg County to close
Fresenius announced it would close its Central City, Kentucky clinic, the only dialysis center in Muhlenberg County, on March 30 without giving a reason, sending patients to Madisonville, Bowling Green or Owensboro. A local nephrologist said nearly 30 of his patients were treated there three times a week; local media in Alabama and Georgia reported similar rural closures.
Ninth Circuit strikes core of California's AB 290 in win for Fresenius and DaVita
The Ninth Circuit held that key provisions of AB 290, including its cap on what dialysis providers that donate to the American Kidney Fund can be paid for patients receiving its premium assistance and its patient disclosure requirement, violate the First Amendment. The ruling preserved the industry's ability to earn commercial rates for AKF-assisted patients, whose private-market costs run far above Medicare's.
Fresenius launches second EUR 1 billion share buyback weeks after completing the first
Fresenius announced a new share buyback program of around EUR 1 billion, to run in tranches over 12 months, only weeks after completing its initial EUR 1 billion program on April 30, 2026, well ahead of its two-year schedule. CEO Helen Giza called it a reflection of the company's unwavering commitment to return capital to shareholders.
Fresenius completes exit of about 100 U.S. dialysis clinics
Fresenius said it had concluded its 2026 optimization of the U.S. clinic footprint by exiting around 100 clinics, retaining most patients in neighboring clinics and expecting higher network efficiency to lift profits. In the same quarter it cancelled all 24.8 million shares bought back under its first program, cutting share capital by 8.5%, and operating income excluding special items rose 23% at constant currency.
5008X hemodiafiltration machines reach 227 U.S. clinics
Fresenius's large-scale U.S. rollout of its 5008X CAREsystem reached 227 clinics and more than 600,000 treatments, including over 100,000 in high-volume hemodiafiltration, a therapy associated in studies with fewer hospitalizations and better survival than conventional hemodialysis. The company aims to replace about 20% of its U.S. dialysis machines in 2026.
Fresenius SE cuts its Fresenius Medical Care stake to about 25%
Fresenius SE sold about 7.8 million Fresenius Medical Care shares, roughly 2.9% of the share capital, to institutional investors for about EUR 300 million, continuing the reduction of what it now treats as a financial investment.
FDA warning letter cites leaking peritoneal dialysis bags at Ogden plant
After a March 2026 inspection, the FDA found Fresenius's Ogden, Utah plant had investigated a complaint trend of leaking Delflex peritoneal dialysis bags in August 2025 (35 complaints, about 156 bags) but assigned it the lowest severity despite its own risk matrix flagging peritonitis, and did not recall the batches until April 2026. The FDA said this exposed patients to potentially non-sterile solution and called the company's response inadequate.
Fresenius investigates cybersecurity incident on internal systems
Fresenius Medical Care said it was investigating unauthorized access to a limited number of internal systems, had contained the incident and notified law enforcement, and that medical devices, patient care and manufacturing were not affected. It did not say whether patient data was accessed.
Evidence (48 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (8 entries)
Checked 85 items + prose. 32 verified, 39 corrected (16 date-only), 12 re-sourced, 2 removed (1 duplicate/unsupported 1997 event, 1 wrong-entity report). Invented details found nowhere: Reynosa plant 'produces 99% of U.S. equipment requirement' (timeline[38]) and a 'EUR 180 million' Cognizant IT outsourcing saving (D9). Major fixes: 8,200 divested employees had been presented as layoffs; Fresenius ballot spend corrected from $68M to about $90M and the industry total from $230M to about $300M; 5,000-job FME25 plan redated to Nov 2021; FTC NxStage concerns re-attributed to dissenting commissioners; several study figures corrected (Eliason paper, duopoly study); parentCompany updated after the 2023 deconsolidation.
65->66. Since Feb 2026 (window from Sep 2025): first EUR 1B buyback completed Apr 2026 (8.5% of shares cancelled) and a second ~EUR 1B program launched May 2026; ~100 U.S. clinics exited in H1 2026 incl. sole rural centers (Macon/Wilcox AL, Muhlenberg KY); delivery outsourced to Ryder with WARN layoffs; FME25+ extended to EUR 1.2B; Ninth Circuit struck AB 290 (Apr 2026); Washington AG noncompete CID (Dec 2025); Blumenthal letter to FTC; FDA warning letter on leaking Delflex bags (Aug 2026); cyber incident (Sep 2026); 5008X HVHDF rollout to 227 clinics; Fresenius SE stake cut to ~25%. FTC/FL/WA probes, UFCW class action and Pepe FCA case all still open. Dimensions: D3 6->7 (event: two back-to-back EUR 1B buybacks alongside ~100 U.S. clinic exits and FME25+ expansion); D6 6->5 (correction: fact audit removed the 4.2% NxStage-share figure; 20-F shows home dialysis at ~16% of FME U.S. treatments, and Fresenius-specific steering evidence is allegation-level); D10 5->6 (recalibration: successful litigation against the 2016 CMS rule and AB 290 plus ~$90M ballot spending and repeated FDA/DOJ matters fit the 6-7 row; the Apr 2026 AB 290 ruling reinforces it). D1, D2, D4, D5, D7, D8, D9 unchanged. Eras: 1996-10-01->1996-09-30, 2000-01-01->2000-01-19, 2006-04-01->2006-03-31, 2012-03-01->2012-02-29, 2019-03-01->2019-02-26 re-dated to their inflection events (labels kept); 'Scandal & Consolidation' split at 2022-12-06 (Giza CEO) into 'Scandal & Consolidation' + new-labeled 'Giza Turnaround'; final era re-dated 2026-02-16 (assessment date)->2025-06-17 (Capital Markets Day / capital allocation framework) and relabeled 'FME25 Extraction'->'Reignite Buyback Era'. All eras re-scored from criteria (E1 25->26, E2 35->36, E3 42->44, E4 50->56, E5 58->61, Giza 64). Added 8 historical events (GranuFlo recall 2012 and 2016 settlement, 2023 FDA tubing warning letter, D.C. AKF subpoena, AG conversion, NLRB complaints, Azura DOJ CID, Aug 2025 pickets) and milestone for 2023 AG conversion.
Empty list kept: duopoly reason still holds. Reworded alternativesReason to match the fact-checked record and the JAMA Health Forum 2025 study (PMC12177639): 77.1% of facilities and 32.5% of the population are 2019 figures (reason had them undated and misphrased the 32.5% as 'areas'). Added the 10.6% independent share (same study), DCI as the largest nonprofit (dciinc.org/about) and the NxStage home-dialysis caveat already in the record.
Checked 13 removed/trimmed sub-claims across 8 candidates: 3 restored, 2 partly restored, 8 confirmed removed. Restored: 1995 HHS OIG investigation start (D. Mass. 2013 ruling, added as evidence); four-fold ESA dose rise 1991-2005 (Am J Nephrol 2017, the originally cited PMC5405152, added as evidence); CMS star-rating measures (Modern Healthcare archive). Partly: flat 1980-2011 Medicare rate squeezing non-chain clinics (LPE Project, added as evidence; lobbying claim left out); 48-60 hour weeks (SEIU-UHW 2024 page, attributed). Confirmed removed: patients not informed, ESA margins funding dividends, DaVita 38 one-star (source says 40), 'industry-leading care' framing, 19th consecutive dividend (6-K says 18th), staffing-ratio link, Reynosa 99% of US equipment, Reynosa 4,500 jobs (not in MedTech Dive or search results).
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).